Biohaven Ltd. — Form 8-K
Filed August 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
SK Biopharmaceuticals Co., Ltd. (SKBP) and Biohaven Bioscience Ireland Limited entered into an exclusive license agreement dated August 26, 2026, for worldwide rights to develop, manufacture, and commercialize Kv7 activators, including BHV-7000 (opakalim), in all indications. SKBP will pay Biohaven $400M upfront ($350M at closing, $50M at 1-year), up to $150M in regulatory milestones, tiered royalties on net sales (reduced for generics/price controls), and assume Knopp Biosciences obligations (~$245M in milestones plus running royalties). Closing is subject to antitrust clearance and other conditions.
Why this rating
Major exclusive platform license deal worth $400M upfront plus $150M+ milestones and double-digit royalties—material to ~$1B company. Transforms Biohaven's monetization of core Kv7 IP but leaves development execution to SKBP; significant near-term cash inflow.
See more from August 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.